Protalix Biotherapeutics 74368CBL7 Bond
PLX Stock | USD 1.69 0.01 0.60% |
At this time, Protalix Biotherapeutics' Net Debt is fairly stable compared to the past year. Short and Long Term Debt Total is likely to rise to about 51.9 M in 2024, whereas Short Term Debt is likely to drop slightly above 18.6 M in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce Protalix Biotherapeutics' Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.25653173 | Current Value 0.49 | Quarterly Volatility 0.29307107 |
Protalix |
Given the importance of Protalix Biotherapeutics' capital structure, the first step in the capital decision process is for the management of Protalix Biotherapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Protalix Biotherapeutics to issue bonds at a reasonable cost.
Popular Name | Protalix Biotherapeutics PL 3218 28 MAR 25 |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US74365A3095 |
Bond Issue ISIN Code | US74368CBL72 |
S&P Rating | Others |
Maturity Date | Others |
Issuance Date | Others |
Protalix Biotherapeutics Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
PL 1618 15 APR 26 | US74368CBC73 | Details | |
US74368CAX20 | US74368CAX20 | Details | |
US743674BE29 | US743674BE29 | Details | |
US74368CAY03 | US74368CAY03 | Details | |
PRXNA 3832 08 FEB 51 | US74365PAE88 | Details | |
PL 5366 06 JAN 26 | US74368CBQ69 | Details | |
PRXNA 4027 03 AUG 50 | US74365PAD06 | Details | |
PRXNA 3257 19 JAN 27 | US74365PAG37 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
PRXNA 3061 13 JUL 31 | US74365PAF53 | Details | |
PRXNA 4193 19 JAN 32 | US74365PAH10 | Details | |
PL 1646 13 JAN 25 | US74368CBJ27 | Details | |
PL 1303 20 SEP 26 | US74368CBH60 | Details | |
PRXNA 368 21 JAN 30 | US74365PAA66 | Details | |
PL 3218 28 MAR 25 | US74368CBL72 | Details | |
PROTECTIVE LIFE P | US743674AY91 | Details | |
PRXNA 4987 19 JAN 52 | US74365PAJ75 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details |
Understaning Protalix Biotherapeutics Use of Financial Leverage
Understanding the structure of Protalix Biotherapeutics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Protalix Biotherapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Net Debt | 2.6 M | 2.8 M | |
Short and Long Term Debt Total | 26.3 M | 51.9 M | |
Short Term Debt | 23.1 M | 18.6 M | |
Long Term Debt | 25.4 M | 28.8 M | |
Short and Long Term Debt | 18.2 M | 34.9 M | |
Long Term Debt Total | 25.4 M | 28.3 M | |
Net Debt To EBITDA | 0.23 | 0.22 | |
Debt To Equity | 0.65 | 0.68 | |
Interest Debt Per Share | 0.37 | 0.35 | |
Debt To Assets | 0.26 | 0.49 | |
Long Term Debt To Capitalization | 1.85 | 1.94 | |
Total Debt To Capitalization | 0.39 | 0.31 | |
Debt Equity Ratio | 0.65 | 0.68 | |
Debt Ratio | 0.26 | 0.49 | |
Cash Flow To Debt Ratio | (0.06) | (0.06) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.